Cole Jon B, Ulici Alexandru, Lee Samantha C, Prekker Matthew E, Driver Brian E, Jurao Arthur R, Olives Travis D
Department of Pharmacy, Hennepin Healthcare, Minnesota Regional Poison Center, Minneapolis, MN, USA.
Department of Emergency Medicine, Hennepin Healthcare, Minneapolis, MN, USA.
Clin Toxicol (Phila). 2025 Jun;63(6):407-419. doi: 10.1080/15563650.2025.2502613. Epub 2025 Jun 4.
High-dose insulin/glucose is an inotrope, vasodilator, and standard therapy for beta-adrenoceptor and calcium channel blocker poisoning, yet no large database studies have examined its use. This study sought to describe high-dose insulin use in the United States using the National Poison Data System. Determining mortality risk factors was the primary aim.
We identified all National Poison Data System® cases in which "High dose insulin/glucose" therapy was Recommended or Performed from 2019 to 2021, the first three years National Poison Data System allowed specific coding for high-dose insulin. We developed logistic regression models to determine clinical factors associated with death in patients receiving high-dose insulin. We also evaluated methylthioninium chloride (methylene blue) use as a refractory vasoplegia marker.
High-dose insulin was used in 1,856 patients, primarily for exposures to calcium channel blockers ( = 1,116 [60%]) and beta-adrenoceptor blockers ( = 985 [53%]), with the most common drugs being amlodipine ( = 677 [61%]) and metoprolol ( = 371 [38%]). Death occurred in 431 [23%] patients; amlodipine was the most common cardiotoxicant in fatal exposures ( = 202 [47%]). Calcium channel blocker exposure was significantly associated with death compared to beta-adrenoceptor blockers (odds ratio 2.2; 95% CI: 1.6-3.8). Exposure to verapamil, compared to amlodipine or diltiazem, was associated with death (odds ratio 1.7; 95% CI: 1.0-2.7). Increasing age, hyperglycemia, heart block, and concomitant treatment with mechanical ventilation or vasopressors were all associated with death. Methylthioninium chloride was more commonly used in patients with amlodipine exposures (110/677 [16%]) than with verapamil or diltiazem (7/325 [2%]; 0.001).
Among patients treated with high-dose insulin, amlodipine-exposed patients were more commonly treated with methylthioninium chloride, suggesting they experienced more refractory vasoplegia. As high-dose insulin is a vasodilator, more data are needed to better define the role for high-dose insulin in amlodipine poisoning.
In this study of patients treated with high-dose insulin, exposure to calcium channel blockers was more lethal than beta-adrenoceptor blocker poisoning. Amlodipine was the most common cardiotoxicant in patients who lived or died, while verapamil was the most lethal cardiotoxicant.
高剂量胰岛素/葡萄糖是一种强心剂、血管扩张剂,也是β肾上腺素能受体和钙通道阻滞剂中毒的标准治疗方法,但尚无大型数据库研究对其使用情况进行过考察。本研究旨在利用国家中毒数据系统描述美国高剂量胰岛素的使用情况。确定死亡风险因素是主要目的。
我们识别了2019年至2021年期间所有在国家中毒数据系统中推荐或实施了“高剂量胰岛素/葡萄糖”治疗的病例,这是国家中毒数据系统允许对高剂量胰岛素进行特定编码的前三年。我们建立了逻辑回归模型,以确定接受高剂量胰岛素治疗患者中与死亡相关的临床因素。我们还评估了亚甲蓝的使用作为难治性血管麻痹的标志物。
1856例患者使用了高剂量胰岛素,主要用于钙通道阻滞剂暴露(1116例[60%])和β肾上腺素能受体阻滞剂暴露(985例[53%]),最常见的药物是氨氯地平(677例[61%])和美托洛尔(371例[38%])。431例(23%)患者死亡;氨氯地平是致命暴露中最常见的心脏毒性药物(202例[47%])。与β肾上腺素能受体阻滞剂相比,钙通道阻滞剂暴露与死亡显著相关(比值比2.2;95%置信区间:1.6 - 3.8)。与氨氯地平或地尔硫䓬相比,维拉帕米暴露与死亡相关(比值比1.7;95%置信区间:1.0 - 2.7)。年龄增加、高血糖、心脏传导阻滞以及机械通气或血管升压药的联合治疗均与死亡相关。氨氯地平暴露患者比亚硝酸异山梨酯或地尔硫䓬暴露患者更常使用亚甲蓝(110/677[16%]比7/325[2%];P<0.001)。
在接受高剂量胰岛素治疗的患者中,氨氯地平暴露患者更常使用亚甲蓝,表明他们经历了更多难治性血管麻痹。由于高剂量胰岛素是一种血管扩张剂,需要更多数据来更好地确定高剂量胰岛素在氨氯地平中毒中的作用。
在这项对接受高剂量胰岛素治疗患者的研究中,钙通道阻滞剂暴露比β肾上腺素能受体阻滞剂中毒更具致死性。氨氯地平是存活或死亡患者中最常见的心脏毒性药物,而维拉帕米是最具致死性的心脏毒性药物。